超早期大剂量尿激酶治疗白发性脑室出血

目的探讨超早期大剂量尿激酶治疗自发性脑室出血的临床疗效。方法将72例自发性脑室出血患者随机分为A组（超早期组）、B组（早期组）、C组（延期组），分别于出血后6～8h、8～72h和72ht之后应用尿激酶治疗。3组均行侧脑室外引流加大剂量尿激酶灌注治疗，术后观察治疗并随访1～6个月。结果1个月后，A组和B组的再出血、感染、继发脑积水率及存活率均优于C组（1P〈0.05）；6个月后，A组日常生活能力（ADI。）显著优于B组和C组（P〈0．05）。结论超早期大剂量尿激酶灌注治疗自发性脑室出血，可降低术后并发症的发生率，提高患者的存活率和生存质量。

Treatment of spontaneous intraventricular hemorrhage with high-dose urokinase in the ultra-early stage

Objective To investigate the clinical effect of high-dose urokinase in treating spontaneous intraventricular hemorrhage in the ultra-early stage. Methods After admission,72 cases of spontaneous intraventricular hemorrhage were randomly divided into group A, B and C. The patients in group A were operated by perfusing with high-dose urokinase within 6-8 hours af- ter bleeding, group B more than 8 hours and less than or equal to 72 hours and group C more than 72 hours. Then they were treated with observation and followed up for 1-6 months. Results Af- ter 1 month, the rates of rehaemorrhagia, infection, secondary hydrocephalus and the survival rate of group A and B were better than group C （P〈0.05）. After 6 months,The ADL of group A was significantly better than group B and C （P〈0.05）. Conclusion Ultra-early perfusion therapy with high-dose urokinase can reduce the incidence of postoperative complications of spon- taneous intraventricular hemorrhage and improve the patients＇ survival rate and quality of life.